Sun YS - Search Results

1

GPC3-targeted CAR-T cells expressing GLUT1 or AGK exhibit enhanced antitumor activity against hepatocellular carcinoma.

Sun RX, Liu YF, Sun YS, Zhou M, Wang Y, Shi BZ, Jiang H, Li ZH. Sun RX, et al. Among authors: sun ys. Acta Pharmacol Sin. 2024 Sep;45(9):1937-1950. doi: 10.1038/s41401-024-01287-8. Epub 2024 May 15. Acta Pharmacol Sin. 2024. PMID: 38750075

2

Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.

Chen M, Sun R, Shi B, Wang Y, Di S, Luo H, Sun Y, Li Z, Zhou M, Jiang H. Chen M, et al. Biomed Pharmacother. 2019 May;113:108734. doi: 10.1016/j.biopha.2019.108734. Epub 2019 Mar 5. Biomed Pharmacother. 2019. PMID: 30849636 Free article.

3

An IL-4/21 Inverted Cytokine Receptor Improving CAR-T Cell Potency in Immunosuppressive Solid-Tumor Microenvironment.

Wang Y, Jiang H, Luo H, Sun Y, Shi B, Sun R, Li Z. Wang Y, et al. Front Immunol. 2019 Jul 19;10:1691. doi: 10.3389/fimmu.2019.01691. eCollection 2019. Front Immunol. 2019. PMID: 31379876 Free PMC article.

4

Target-Dependent Expression of IL12 by synNotch Receptor-Engineered NK92 Cells Increases the Antitumor Activities of CAR-T Cells.

Luo H, Wu X, Sun R, Su J, Wang Y, Dong Y, Shi B, Sun Y, Jiang H, Li Z. Luo H, et al. Front Oncol. 2019 Dec 19;9:1448. doi: 10.3389/fonc.2019.01448. eCollection 2019. Front Oncol. 2019. PMID: 31921693 Free PMC article.

5

Coexpression of IL7 and CCL21 Increases Efficacy of CAR-T Cells in Solid Tumors without Requiring Preconditioned Lymphodepletion.

Luo H, Su J, Sun R, Sun Y, Wang Y, Dong Y, Shi B, Jiang H, Li Z. Luo H, et al. Clin Cancer Res. 2020 Oct 15;26(20):5494-5505. doi: 10.1158/1078-0432.CCR-20-0777. Epub 2020 Aug 14. Clin Cancer Res. 2020. PMID: 32816947

6

Olaparib Suppresses MDSC Recruitment via SDF1α/CXCR4 Axis to Improve the Anti-tumor Efficacy of CAR-T Cells on Breast Cancer in Mice.

Sun R, Luo H, Su J, Di S, Zhou M, Shi B, Sun Y, Du G, Zhang H, Jiang H, Li Z. Sun R, et al. Mol Ther. 2021 Jan 6;29(1):60-74. doi: 10.1016/j.ymthe.2020.09.034. Epub 2020 Sep 26. Mol Ther. 2021. PMID: 33010818 Free PMC article.

7

Chimeric anti-GPC3 sFv-CD3ε receptor-modified T cells with IL7 co-expression for the treatment of solid tumors.

Sun Y, Dong Y, Sun R, Liu Y, Wang Y, Luo H, Shi B, Jiang H, Li Z. Sun Y, et al. Mol Ther Oncolytics. 2022 Apr 19;25:160-173. doi: 10.1016/j.omto.2022.04.003. eCollection 2022 Jun 16. Mol Ther Oncolytics. 2022. PMID: 35572194 Free PMC article.

8

Enforced expression of Runx3 improved CAR-T cell potency in solid tumor via enhancing resistance to activation-induced cell death.

Wang Y, Zhang H, Du G, Luo H, Su J, Sun Y, Zhou M, Shi B, Li HQX, Jiang H, Li Z. Wang Y, et al. Mol Ther. 2023 Mar 1;31(3):701-714. doi: 10.1016/j.ymthe.2022.12.009. Epub 2022 Dec 15. Mol Ther. 2023. PMID: 36523165 Free PMC article.

9

FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer.

Liu Y, Sun Y, Wang P, Li S, Dong Y, Zhou M, Shi B, Jiang H, Sun R, Li Z. Liu Y, et al. J Transl Med. 2023 Apr 12;21(1):255. doi: 10.1186/s12967-023-04080-z. J Transl Med. 2023. PMID: 37046312 Free PMC article.

10

CXCR4-modified CAR-T cells suppresses MDSCs recruitment via STAT3/NF-κB/SDF-1α axis to enhance efficacy against pancreatic cancer.

Sun R, Sun Y, Wu C, Liu Y, Zhou M, Dong Y, Du G, Luo H, Shi B, Jiang H, Li Z. Sun R, et al. Mol Ther. 2023 Nov 1;31(11):3193-3209. doi: 10.1016/j.ymthe.2023.09.010. Epub 2023 Sep 20. Mol Ther. 2023. PMID: 37735875 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

515 results

Search Page

Filters